MOPEAD – Models of Patient Engagement for Alzheimer’s Disease

October 5, 2017

Novel Research to improve timely diagnosis of Alzheimer’s disease (AD) through citizen participation. 

Today, a significant proportion of people with dementia are not diagnosed and, consequently, do not have access to available care and treatment. This also deprives them of having the opportunity to participate in clinical trials at early stages of the disease if these are available.
The aim of MOPEAD is to contribute to redress the situation: the project will assess different Patient Engagement models across Europe that will help identify subjects with mild cognitive impairment and mild AD dementia (an early stage of the disease in which patients experience cognitive impairment and problems but are still autonomous).
MOPEAD has the potential to contribute to move the AD Environment towards earlier diagnosis to improve identification of appropriate patients for disease modifying therapies.

Share on Facebook
Share on Twitter
Please reload

Please reload

Please reload

Search By Tags
Follow Us
  • Facebook Basic Square
  • Twitter Basic Square
  • Google+ Basic Square

©2019 MOPEAD

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreement No 115985. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations